STRIDES ARCOLAB ANNOUNCES HEALTH CANADA APPROVAL FOR TOBRAMYCIN INJECTION

- Approval under expedited review process due to shortage

April 2, 2012, Bangalore: Strides Arcolab Limited (Strides) today announced that its Canadian subsidiary has received approval from Health Canada for Tobramycin Injection USP 40 mg / mL, Liquid dosage form.

The approval was granted under the expedited review process being adopted by Health Canada to address the severe drug shortage situation in Canada. In March 2012, Canadian Health Ministry had indicated that Health Canada will approve suppliers within a month to ease the drug shortage in Canada. The Market value of the product is approximately USD 4.2 Million.

The product will be commercialized in Q2 of 2012 directly by Strides Canadian subsidiary.

About Tobramycin

Tobramycin is in a group of antibiotics called aminoglycosides used to treat bacterial infections of the skin, heart, stomach, brain and spinal cord, respiratory system, and urinary tract. It is also used in the treatment of cystic fibrosis. Tobramycin injection is sometimes used together with other antibiotics.

About Agila Specialties

Agila is the specialties unit of Strides Arcolab which was spun off as a separate division post the Company’s restructuring in 2009. It is focused on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 8 world-class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila’s marketing network covers 70 countries and it has partnerships with some of the world’s leading pharmaceutical companies for both developed and emerging markets.
**About Strides Arcolab Limited**

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 13 manufacturing facilities across 5 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company’s website at www.stridesarco.com.

For further information, please contact:

<table>
<thead>
<tr>
<th>Strides</th>
<th>PR Consultancy</th>
</tr>
</thead>
</table>
| Mr. V.S. Iyer, CEO - Agila  
+91 80 6784 0111  
Mr. Ajay Singh : +91 80 6784 0813  
Mr. Kannan N : +91 98450 54745 (Investors) | Corporate Voice | Weber Shandwick |
|               | Mahesh Nair,  
+91 9880376648  
[maheeshn@corvoshandwick.co.in](mailto:maheeshn@corvoshandwick.co.in) |               |
|               | Kaveri Mandanna,  
+91 90089 59697  
[kaveri@corvoshandwick.co.in](mailto:kaveri@corvoshandwick.co.in) |               |